Interactions between genetic and environmental factors are thought to contribute to the pathogenesis of the majority of Parkinson’s disease (PD) cases. However, our understanding of these interactions is at an early stage. Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common cause of hereditary PD. Penetrance of LRRK2 mutations is incomplete and variable, suggesting that other environmental or genetic factors may contribute to the development of the disorder. Recently, using animal models, several attempts have been made to understand if LRRK2 may mediate sensitivity to environmental neurotoxicants. Here, we critically review the most current data on how LRRK2 mutations influence neurotoxicity in PD models.
BraakHDel TrediciKRubUde VosRAJansen SteurENBraakE. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging2003; 24: 197–211.
3.
ShulmanJMDe JagerPLFeanyMB. Parkinson’s disease: genetics and pathogenesis. Annu Rev Pathol2011; 6: 193–222.
4.
CannonJRGreenamyreJT. Neurotoxic in vivo models of Parkinson’s disease recent advances. Prog Brain Res2010; 184: 17–33.
5.
CannonJRTapiasVNaHMHonickASDroletREGreenamyreJT. A highly reproducible rotenone model of Parkinson’s disease. Neurobiol Dis2009; 34: 279–290.
6.
LangstonJWBallardPTetrudJWIrwinI. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science1983; 219: 979–980.
7.
LangstonJWFornoLSTetrudJReevesAGKaplanJAKarlukD. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol1999; 46: 598–605.
8.
DengYNewmanBDunneMPSilburnPAMellickGD. Further evidence that interactions between CYP2D6 and pesticide exposure increase risk for Parkinson’s disease. Ann Neurol2004; 55: 897–897.
9.
ElbazALevecqueCClavelJVidalJSRichardFAmouyelPAlperovitchAChartier-HarlinMCTzourioC. CYP2D6 polymorphism, pesticide exposure, and Parkinson’s disease. Ann Neurol2004; 55: 430–4.
10.
GattoNMRhodesSLManthripragadaADBronsteinJCockburnMFarrerMRitzB. alpha-Synuclein gene may interact with environmental factors in increasing risk of Parkinson’s disease. Neuroepidemiology2010; 35: 191–5.
11.
RitzBRManthripragadaADCostelloSLincolnSJFarrerMJCockburnMBronsteinJ. Dopamine transporter genetic variants and pesticides in Parkinson’s disease. Environ Health Perspect2009; 117: 964–9.
12.
ClarkIEDodsonMWJiangCCaoJHHuhJRSeolJHYooSJHayBAGuoM. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature2006; 441: 1162–6.
13.
PolymeropoulosMHLavedanCLeroyEIdeSEDehejiaADutraAPikeBRootHRubensteinJBoyerRStenroosESChandrasekharappaSAthanassiadouAPapapetropoulosTJohnsonWGLazzariniAMDuvoisinRCDi IorioGGolbeLINussbaumRL. Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science1997; 276: 2045–7.
14.
ZimprichABiskupSLeitnerPLichtnerPFarrerMLincolnSKachergusJHulihanMUittiRJCalneDBStoesslAJPfeifferRFPatengeNCarbajalICViereggePAsmusFMuller-MyhsokBDicksonDWMeitingerTStromTMWszolekZKGasserT. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron2004; 44: 601–7.
15.
MuenterMDFornoLSHornykiewiczOKishSJMaraganoreDMCaselliRJOkazakiHHowardFMJr.SnowBJCalneDB. Hereditary form of parkinsonism—dementia. Ann Neurol1998; 43: 768–81.
16.
SingletonABFarrerMJohnsonJSingletonAHagueSKachergusJHulihanMPeuralinnaTDutraANussbaumRLincolnSCrawleyAHansonMMaraganoreDAdlerCCooksonMRMuenterMBaptistaMMillerDBlancatoJHardyJGwinn-HardyK. alpha-Synuclein locus triplication causes Parkinson’s disease. Science2003; 302: 841–841.
17.
TsuboiY. Environmental-genetic interactions in the pathogenesis of Parkinson’s disease. Exp Neurobiol2012; 21: 123–8.
18.
GilksWPAbou-SleimanPMGandhiSJainSSingletonALeesAJShawKBhatiaKPBonifatiVQuinnNPLynchJHealyDGHoltonJLReveszTWoodNW. A common LRRK2 mutation in idiopathic Parkinson’s disease. Lancet2005; 365: 415–6.
19.
HealyDGFalchiMO’SullivanSSBonifatiVDurrABressmanSBriceAAaslyJZabetianCPGoldwurmSFerreiraJJTolosaEKayDMKleinCWilliamsDRMarrasCLangAEWszolekZKBercianoJSchapiraAHLynchTBhatiaKPGasserTLeesAJWoodNW. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson’s disease: a case-control study. Lancet Neurol2008; 7: 583–90.
20.
DawsonTMKoHSDawsonVL. Genetic animal models of Parkinson’s disease. Neuron2010; 66: 646–61.
21.
CooksonMR. The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson’s disease. Nat Rev Neurosci2010; 11: 791–7.
22.
DaviesPHinkleKMSukarNNSepulvedaBMesiasRSerranoGAlessiDRBeachTGBensonDLWhiteCLCowellRMDasSSWestABMelroseHL. Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodies. Biochem J2013; 453: 101–13.
23.
BiskupSWestAB. Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson’s disease. Biochim Biophys Acta2009; 1792: 625–33.
24.
GloecknerCJSchumacherABoldtKUeffingM. The Parkinson disease-associated protein kinase LRRK2 exhibits MAPKKK activity and phosphorylates MKK3/6 and MKK4/7, in vitro. J Neurochem2009; 109: 959–68.
25.
MacLeodDDowmanJHammondRLeeteTInoueKAbeliovichA. The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron2006; 52: 587–93.
26.
MartinIKimJWDawsonVLDawsonTM. LRRK2 pathobiology in Parkinson’s disease. J Neurochem2014; 131: 554–65.
PiccoliGCondliffeSBBauerMGiesertFBoldtKDe AstisSMeixnerASariogluHVogt-WeisenhornDMWurstWGloecknerCJMatteoliMSalaCUeffingM. LRRK2 controls synaptic vesicle storage and mobilization within the recycling pool. J Neurosci2011; 31: 2225–2237.
29.
RossOASoto-OrtolazaAIHeckmanMGAaslyJOAbahuniNAnnesiGBaconJABardienSBoziMBriceABrighinaLVan BroeckhovenCCarrJChartier-HarlinMCDardiotisEDicksonDWDiehlNNElbazAFerrareseCFerrarisAFiskeBGibsonJMGibsonRHadjigeorgiouGMHattoriNIoannidisJPJasinska-MygaBJeonBSKimYJKleinCKrugerRKyratziELesageSLinCHLynchTMaraganoreDMMellickGDMutezENilssonCOpalaGParkSSPuschmannAQuattroneASharmaMSilburnPASohnYHStefanisLTadicVTheunsJTomiyamaHUittiRJValenteEMvan de LooSVassilatisDKVilarino-GuellCWhiteLRWirdefeldtKWszolekZKWuRMFarrerMJ. Association of LRRK2 exonic variants with susceptibility to Parkinson’s disease: a case-control study. Lancet Neurol2011; 10: 898–908.
30.
KettLRDauerWT. Leucine-rich repeat kinase 2 for beginners: six key questions. Cold Spring Harb Perspect Med2012; 2: a009407–a009407.
31.
GreggioEJainSKingsburyABandopadhyayRLewisPKaganovichAvan der BrugMPBeilinaABlackintonJThomasKJAhmadRMillerDWKesavapanySSingletonALeesAHarveyRJHarveyKCooksonMR. Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis2006; 23: 329–41.
32.
LeeBDShinJHVanKampenJPetrucelliLWestABKoHSLeeYIMaguire-ZeissKABowersWJFederoffHJDawsonVLDawsonTM. Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson’s disease. Nat Med2010; 16: 998–1000.
YangDLiTLiuZArbezNYanJMoranTHRossCASmithWW. LRRK2 kinase activity mediates toxic interactions between genetic mutation and oxidative stress in a Drosophila model: suppression by curcumin. Neurobiol Dis2012; 47: 385–92.
35.
TrinhJGustavssonEKGuellaIVilarino-GuellCEvansDEncarnacionMShermanHHentatiFFarrerMJ. The role of SNCA and MAPT in Parkinson disease and LRRK2 parkinsonism in the Tunisian Arab-Berber population. Eur J Neurol2014; 21: e91–92.
36.
TrinhJGuellaIFarrerMJ. Disease penetrance of late-onset parkinsonism: A meta-analysis. JAMA neurology2014; 71: 1535–9.
37.
WestABMooreDJChoiCAndrabiSALiXDikemanDBiskupSZhangZLimKLDawsonVLDawsonTM. Parkinson’s disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum Mol Genet2007; 16: 223–232.
MarinI. Ancient origin of the Parkinson disease gene LRRK2. J Mol Evol2008; 67: 41–50.
40.
ImaiYGehrkeSWangHQTakahashiRHasegawaKOotaELuB. Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. EMBO J2008; 27: 2432–43.
41.
WangDTangBZhaoGPanQXiaKBodmerRZhangZ. Dispensable role of Drosophila ortholog of LRRK2 kinase activity in survival of dopaminergic neurons. Mol Neurodegener2008; 3: 3–3.
42.
LeeSBKimWLeeSChungJ. Loss of LRRK2/PARK8 induces degeneration of dopaminergic neurons in Drosophila. Biochem Biophys Res Commun2007; 358: 534–9.
43.
NgCHMokSZKohCOuyangXFivazMLTanEKDawsonVLDawsonTMYuFLimKL. Parkin protects against LRRK2 G2019S mutant-induced dopaminergic neurodegeneration in Drosophila. J Neurosci2009; 29: 11257–62.
LiuXYamadaNMaruyamaWOsawaT. Formation of dopamine adducts derived from brain polyunsaturated fatty acids: mechanism for Parkinson disease. J Biol Chem2008; 283: 34887–95.
46.
LiuZHamamichiSLeeBDYangDRayACaldwellGACaldwellKADawsonTMSmithWWDawsonVL. Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson’s disease models. Hum Mol Genet2011; 20: 3933–42.
47.
VenderovaKKabbachGAbdel-MessihEZhangYParksRJImaiYGehrkeSNgseeJLavoieMJSlackRSRaoYZhangZLuBHaqueMEParkDS. Leucine-Rich Repeat Kinase 2 interacts with Parkin, DJ-1 and PINK-1 in a Drosophila melanogaster model of Parkinson’s disease. Hum Mol Genet2009; 18: 4390–4404.
48.
DaherJPVolpicelli-DaleyLABlackburnJPMoehleMSWestAB. Abrogation of alpha-synuclein-mediated dopaminergic neurodegeneration in LRRK2-deficient rats. Proc Natl Acad Sci USA2014; 111: 9289–94.
WestABCowellRMDaherJPMoehleMSHinkleKMMelroseHLStandaertDGVolpicelli-DaleyLA. Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodents. J Comp Neurol2014; 522: 2465–80.
51.
SahaSGuillilyMDFerreeALancetaJChanDGhoshJHsuCHSegalLRaghavanKMatsumotoKHisamotoNKuwaharaTIwatsuboTMooreLGoldsteinLCooksonMWolozinB. LRRK2 modulates vulnerability to mitochondrial dysfunction in Caenorhabditis elegans. J Neurosci2009; 29: 9210–8.
52.
YaoCEl KhouryRWangWByrdTAPehekEAThackerCZhuXSmithMAWilson-DelfosseALChenSG. LRRK2-mediated neurodegeneration and dysfunction of dopaminergic neurons in a Caenorhabditis elegans model of Parkinson’s disease. Neurobiol Dis2010; 40: 73–81.
53.
RayAMartinezBABerkowitzLACaldwellGACaldwellKA. Mitochondrial dysfunction, oxidative stress, and neurodegeneration elicited by a bacterial metabolite in a C.elegans Parkinson’s model. Cell Death Dis2014; 5: e984–e984.
54.
SamannJHegermannJvon GromoffEEimerSBaumeisterRSchmidtE. Caenorhabditits elegans LRK-1 and PINK-1 act antagonistically in stress response and neurite outgrowth. J Biol Chem2009; 284: 16482–91.
55.
Andres-MateosEMejiasRSasakiMLiXLinBMBiskupSZhangLBanerjeeRThomasBYangLLiuGBealMFHusoDLDawsonTMDawsonVL. Unexpected lack of hypersensitivity in LRRK2 knock-out mice to MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine). J Neurosci2009; 29: 15846–50.
56.
LinXParisiadouLGuXLWangLShimHSunLXieCLongCXYangWJDingJChenZZGallantPETao-ChengJHRudowGTroncosoJCLiuZLiZCaiH. Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson’s-disease-related mutant alpha-synuclein. Neuron2009; 64: 807–27.
57.
TongYYamaguchiHGiaimeEBoyleSKopanRKelleherRJ3rdShenJ. Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice. Proc Natl Acad Sci USA2010; 107: 9879–84.
58.
TongYPisaniAMartellaGKarouaniMYamaguchiHPothosENShenJ. R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice. Proc Natl Acad Sci USA2009; 106: 14622–7.
59.
HerzigMCBidinostiMSchweizerTHafnerTStemmelenCWeissADannerSVidottoNStaufferDBarskeCMayerFSchmidPRovelliGvan der PuttenPHShimshekDR. High LRRK2 levels fail to induce or exacerbate neuronal alpha-synucleinopathy in mouse brain. PLoS One2012; 7: e36581–e36581.
60.
LiXPatelJCWangJAvshalumovMVNicholsonCBuxbaumJDElderGARiceMEYueZ. Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson’s disease mutation G2019S. J Neurosci2010; 30: 1788–1797.
61.
LiYLiuWOoTFWangLTangYJackson-LewisVZhouCGeghmanKBogdanovMPrzedborskiSBealMFBurkeRELiC. Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson’s disease. Nat Neurosci2009; 12: 826–8.
62.
MelroseHLDachselJCBehrouzBLincolnSJYueMHinkleKMKentCBKorvatskaETaylorJPWittenLLiangYQBeeversJEBoulesMDuggerBNSernaVAGaukhmanAYuXCastanedes-CaseyMBraithwaiteATOgholikhanSYuNBassDTyndallGSchellenbergGDDicksonDWJanusCFarrerMJ. Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice. Neurobiol Dis2010; 40: 503–17.
DusonchetJKochubeyOStafaKYoungSMJr.ZuffereyRMooreDJSchneiderBLAebischerP. A rat model of progressive nigral neurodegeneration induced by the Parkinson’s disease-associated G2019S mutation in LRRK2. J Neurosci2011; 31: 907–12.
66.
GiassonBICovyJPBoniniNMHurtigHIFarrerMJTrojanowskiJQVan DeerlinVM. Biochemical and pathological characterization of Lrrk2. Ann Neurol2006; 59: 315–22.
67.
DesplatsPPatelPKosbergKManteMPatrickCRockensteinEFujitaMHashimotoMMasliahE. Combined exposure to Maneb and Paraquat alters transcriptional regulation of neurogenesis-related genes in mice models of Parkinson’s disease. Mol Neurodegener2012; 7: 49–49.
68.
LiTYangDZhongSThomasJMXueFLiuJKongLVoulalasPHassanHEParkJSMacKerellADJr.SmithWW. Novel LRRK2 GTP-binding inhibitors reduced degeneration in Parkinson’s disease cell and mouse models. Hum Mol Genet2014; 23: 6212–22.
69.
CannonJRGreenamyreJTRotenone as preclinical model compound in Parkinson disease. In: KostrzewaRM (ed). Handbook of neurotoxicity, New York: Springer, 2014, pp. 995–1012.
